Prurigo Nodularis IGA Severity

Assess prurigo nodularis (PN) severity using IGA 0-4 scale. IGA 0/1 response with >=2 grade improvement is the primary endpoint for dupilumab (LIBERTY-PN PRIME) and nemolizumab.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Assess prurigo nodularis (PN) severity using IGA 0-4 scale. IGA 0/1 response with >=2 grade improvement is the primary endpoint for dupilumab (LIBERTY-PN PRIME) and nemolizumab

Each component has a specific meaning:

  • IGA 0-4 scale — The iga 0-4 scale recorded for the scenario being assessed.

Note: Interpret the pn iga severity result against the thresholds and context described above.

How to Use

Enter the IGA 0-4 scale for the scenario you are assessing. Assess prurigo nodularis (PN) severity using IGA 0-4 scale. IGA 0/1 response with >=2 grade improvement is the primary endpoint for dupilumab (LIBERTY-PN PRIME) and nemolizumab. Use the pn iga severity result to inform your calculation.

Related Calculators

IGA Atopic Dermatitis

Hyper-niche Medical

EASI Score

Hyper-niche Medical

Frequently Asked Questions